Treatment of Uncomplicated Typhoid Fever
For uncomplicated typhoid fever, azithromycin or ceftriaxone should be used as first-line therapy, with the choice guided by local resistance patterns and route of administration preference. 1
Antibiotic Selection Algorithm
First-Line Options
Azithromycin is the preferred oral agent for uncomplicated typhoid fever, particularly in regions with high fluoroquinolone resistance (which now includes most endemic areas). 1
- Dosing: 20 mg/kg/day orally for 7-14 days 2, 3
- Advantages: Lower clinical failure rates (OR 0.48) compared to fluoroquinolones, shorter hospital stays (-1.04 days), and significantly lower relapse rates (OR 0.09) compared to ceftriaxone 1
- Clinical performance: Fever clearance time of approximately 5.8 days, with 85% clinical cure rate 2
- Safety: Well-tolerated with no serious adverse events reported 4, 5
Ceftriaxone is the preferred parenteral agent when oral therapy is not feasible or the patient is clinically unstable. 1
- Dosing: Intravenous administration (standard dosing)
- Rationale: Over 70% of S. typhi and S. paratyphi isolates imported into endemic regions are fluoroquinolone-resistant, but all remain sensitive to ceftriaxone 1
- Duration: 14 days to reduce relapse risk 1
- Performance: May result in decreased clinical failure compared to azithromycin (RR 0.42), though time to defervescence may be 0.52 days longer 6
Second-Line and Alternative Options
Fluoroquinolones (ciprofloxacin, gatifloxacin, ofloxacin) should only be used if the isolate is confirmed sensitive to nalidixic acid. 1
- Critical caveat: Ciprofloxacin disc testing alone is unreliable; nalidixic acid sensitivity must be confirmed 1
- Current resistance: 88-96% of isolates in South Asia are nalidixic acid-resistant, making fluoroquinolones ineffective in most cases 2, 3
- When appropriate: If fully sensitive, fluoroquinolones offer fever clearance <4 days with >96% cure rates 1
Cefixime is an oral alternative but has inferior performance compared to other options. 6, 2
- Limitations: Clinical failure rates may be increased (RR 13.39) compared to fluoroquinolones, with longer fever clearance times (+1.74 days) 6
- Treatment failure rates: Reported as 4-37.6% when used as first-line 1
- Combination therapy: Cefixime-ofloxacin combination shows promise in Indian settings with ~3-day defervescence time, though this is not widely recommended 7
Critical Resistance Considerations
Extensively drug-resistant (XDR) typhoid has emerged, particularly from Pakistan since 2016. 8, 9
- Definition: Resistant to chloramphenicol, ampicillin, trimethoprim-sulfamethoxazole, fluoroquinolones, and third-generation cephalosporins 8, 9
- Implication: Azithromycin remains effective, though azithromycin resistance is beginning to emerge 8
Multidrug-resistant (MDR) typhoid (resistant to chloramphenicol, ampicillin, trimethoprim-sulfamethoxazole) is common, affecting 58-88.7% of isolates in endemic regions. 2, 3
Treatment Duration and Monitoring
Standard treatment duration is 7-14 days, with 14 days preferred to minimize relapse risk. 1, 2
- Relapse rates: Ceftriaxone <8%, azithromycin <3%, fluoroquinolones variable 1
- Outpatient management: Safe and effective for uncomplicated cases using oral azithromycin for 7 days, with careful monitoring 5
Common Pitfalls to Avoid
Do not use older first-line antibiotics (chloramphenicol, ampicillin, trimethoprim-sulfamethoxazole) as empiric therapy due to widespread resistance and higher clinical failure rates. 1
Do not rely on fluoroquinolones empirically in patients returning from South Asia or other high-resistance areas without confirmed susceptibility testing. 1, 2
Do not use cefixime as monotherapy when azithromycin or ceftriaxone are available, given its inferior performance. 6
Do not assume ciprofloxacin disc sensitivity indicates true fluoroquinolone susceptibility; nalidixic acid testing is mandatory. 1